Jorge Azinheira

Learn More
PURPOSE To determine whether hyperhomocysteinemia represents a risk factor of early thrombotic cerebrovascular disease. METHOD In a group of patients under 55 years of age (n = 33, 19 males) which had suffered a stroke from 3 months to 1 year before the study, defined by clinical criteria and presence of cerebral infarction confirmed by tomography,(More)
BACKGROUND Homocysteinaemia is now accepted as an independent risk factor for coronary artery disease (CAD). Our goal was to study the influence of age plasma homocysteine level on the CAD risk attributable to homocysteinaemia. METHODS We studied a group of 98 patients under 55 years of age who had suffered a myocardial infarction 3-12 months before the(More)
PURPOSE To evaluate importance of homocysteinemia as risk factor of thrombotic cerebrovascular disease, in terms of age and homocysteinemia levels. METHODS A group of patients under 55 years old (n = 35, 21 males) that had suffered a stroke 3 months to 1 year before the study, defined by clinical criteria and the presence of cerebral infarction confirmed(More)
INTRODUCTION AND AIMS Homocysteinemia is an independent risk factor of coronary artery disease and of myocardial infarction. In the present study we intend to relate fasting homocystein levels to prognosis after a myocardial infarction. METHODS From 1990 to 1992, we studied fasting homocysteinemia levels on a group of 112 patients aged under 56 years that(More)
INTRODUCTION AND AIMS Homocysteinemia (HC) and smoking are both important risk factors for vascular disease. In the present study, we intend to evaluate the influence of smoking habits on HC values as well as on vitamins B6, B12 and folic acid, co-factors of HC metabolism. METHODS We measured fasting homocysteinemia (basal) and homocysteinemia 6 hours(More)
INTRODUCTION AND OBJECTIVES We have already proved that basal and after load homocysteinemia are risk factors for vascular disease and it is also known that premenopausal women are relatively protected against this disease. The objective of this paper was the assess whether there are any differences in the plasma levels of homocystein which might contribute(More)
BACKGROUND Metformin is the cornerstone of the pharmacological therapy for type 2 Diabetes (T2D). It belongs to the biguanide class of drugs and it improves hepatic insulin resistance and enhances GLP-1 and peptide YY secretion. Although being considered safe regarding hypoglycemic risk, renal dysfunction remains the main obstacle to its use due to the(More)